Work Here?
Overview
BridgeBio Pharma develops medicines for genetic diseases through a decentralized subsidiary model, with each subsidiary focused on a specific disease while sharing central resources. It advances multiple drug programs at once by using genome sequencing, molecular biology, and patient data to identify targets and translate research into therapies. Therapies target the underlying genetic causes to create disease-modifying treatments, and BridgeBio monetizes via licensing, partnerships, and eventual commercialization of approved drugs. The company differentiates itself by its independent subsidiaries with centralized support, data-driven decision making, and a culture of radical transparency, all to accelerate discovery and bring therapies to patients faster.
About BridgeBio
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2014
People at BridgeBio
People at BridgeBio who can refer or advise you
Simplify's Take
What believers are saying
- BBP-418 met all Phase 3 FORTIFY endpoints in LGMD2I/R9, showing ~1.8x αDG increase and 82% CK reduction, enabling NDA submission March 2026.
- Attruby demonstrated 44.7% all-cause mortality reduction through month 54, solidifying market leadership in ATTR-CM.
- DKSH partnership in June 2026 expands ATTR-CM stabilizer access across Australia, Singapore, South Korea, and Taiwan.
What critics are saying
- Pfizer's YP-145 enters Phase 3 Q4 2026 with superior half-life, threatening Attruby dominance within 12–18 months, 45–60% probability.
- DKSH may fail regulatory approval for acoramidis in Australia/South Korea by end-2026 due to labeling disputes, blocking $40M+ Asia revenue, 35–50% probability.
- BBP-418 could face FDA rejection for LGMD2I/R9 if long-term pediatric safety data deemed inadequate, invalidating diversification and triggering $200M+ dilution, 40–55% probability.
What makes BridgeBio unique
- Decentralized hub-and-spoke model enables autonomous teams to target specific genetic diseases with shared central resources.
- Focuses exclusively on genetic diseases with well-understood underlying causes, accelerating translational medicine development.
- Leverages breakthroughs in genome sequencing and patient databases to identify and develop therapies for rare conditions.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$4.4B
Above
Industry Average
Funded Over
14 Rounds
Benefits
Health Insurance
Performance Bonus
Company Equity
Unlimited Paid Time Off
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 3%BridgeBio Pharma has fallen 8% over the past month and 7% over three months, despite posting a 110.52% one-year total shareholder return and approximately 4x returns over three years. The company closed at $69.41, with analysts from Vestra pointing to a fair value of $100.05, suggesting it's 30.6% undervalued. The valuation gap depends on BridgeBio's late-stage pipeline and its transition from research and development to commercial operations. However, the company continues to carry annual net losses of approximately $724.9 million, keeping financing and execution risks prominent. A separate DCF model estimates future cash flow value at $302.08, though this relies heavily on long-term assumptions around successful regulatory approvals and commercial uptake across its rare disease portfolio.
BridgeBio Pharma announced positive interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9, meeting efficacy endpoints. The company will present expanded results at the 2026 MDA Clinical and Scientific Conference alongside additional research. The successful readout represents a significant step for BBP-418 as a potential therapy for the rare genetic muscle disorder and could help diversify BridgeBio's revenue beyond its single approved drug, Attruby. However, the company remains unprofitable, reporting US$502 million in revenue against a US$725 million net loss in 2025. Analysts project BridgeBio could reach US$1.7 billion in revenue by 2028, with a fair value estimate of US$100.05 per share. The key risk remains high cash burn and potential dilution if expenses continue outpacing revenue growth.
BridgeBio Pharma has received upgraded price targets from analysts following strong fourth-quarter results. Truist raised its target to $95 from $86, maintaining a Buy rating, whilst Morgan Stanley increased its target to $98 from $96 with an Overweight rating. The company reported fourth-quarter revenue of $154.18 million, exceeding the $149.07 million consensus estimate. Pre-announced sales of its drug Attruby reached $146 million, a 35% increase from the third quarter, driven by accelerating new patient additions. CEO Neil Kumar highlighted the company's delivery of three successful Phase 3 trial readouts within three months. BridgeBio develops medicines for patients with genetic diseases and anticipates having six approved products as it completes its first decade.
BridgeBio Pharma has received positive analyst coverage following strong 2025 results. Truist raised its price target to $86 from $80 whilst maintaining a Buy rating, noting unchanged fundamental views from 2025. At the J.P. Morgan Healthcare Conference on 12 January, BridgeBio announced preliminary unaudited revenues of $146 million for the fourth quarter of 2025, bringing full-year product revenue to $362.4 million. The company reported over 6,000 unique prescriptions for Attruby, demonstrating rapid market adoption as a first-choice treatment for newly diagnosed ATTR-CM patients. BridgeBio develops therapies for genetic diseases and cancers, including its oncology-focused spin-off, BridgeBio Oncology Therapeutics, which advances precision cancer treatments targeting oncogenes like RAS and PI3K.
BridgeBio has priced an offering of $550 million in convertible senior notes due 2033. The biotech company plans to use the proceeds to prefund the repayment of its existing convertible senior notes due 2027. The refinancing move allows BridgeBio to extend its debt maturity profile by six years whilst managing its capital structure ahead of the 2027 notes coming due.
BridgeBio is Hiring for 105 Jobs on Simplify!
Find jobs on Simplify and start your career today
About BridgeBio
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2014
BridgeBio is Hiring for 105 Jobs on Simplify!
Find jobs on Simplify and start your career today